Mazdutide vs Survodutide
The table compares the compounds’ key data from their entry pages. Open each compound’s full entry for details. Educational content, not medical advice.
Mazdutide (IBI362) | Survodutide | |
|---|---|---|
| What it is | Obesity drug acting on GLP-1 and glucagon, approved in China in 2025; elsewhere still investigational. | Experimental obesity and diabetes medicine in late-stage trials that imitates glucagon and GLP-1. |
| Type | GLP-1 / glucagon dual agonist | Glucagon / GLP-1 dual agonist |
| Structure | Oxyntomodulin-based analog | Lipidated 29-aa glucagon analog |
| Status | Approved in China (2025) | Phase 3 |
| Route | SC, once weekly | SC, once weekly |
| Storage | 2–8°C | 2–8°C |
| Full entry | Open → | Open → |
Mazdutide or survodutide: what is the difference?
Both copy the action of two hormones at once, GLP-1 and glucagon, and both are being developed to treat obesity. Their structures differ: according to its entry mazdutide is an oxyntomodulin-based analog, while survodutide is a lipidated glucagon analog of 29 amino acids. Mazdutide is a joint project of Innovent Biologics and Eli Lilly; survodutide is being studied not only for obesity but also for type 2 diabetes and MASH, metabolic-related fatty liver inflammation. The biggest difference is status: mazdutide was approved in China in 2025 for obesity and is investigational elsewhere, while survodutide is not yet approved and is being tested in late-stage, phase 3 human trials.

